Key result
A 78-year-old female with acute coronary syndrome developed a rare intraparenchymal hepatic hemorrhage following a loading dose of ticagrelor, resolving after de-escalation to clopidogrel.
Why the study?
Intrahepatic hemorrhages have been reported with anticoagulant drugs, but no case due to ticagrelor had been reported in the literature.
Case Report (n=1)
No
Ticagrelor loading in elderly patients with acute coronary syndrome may cause rare but severe bleeding complications such as intraparenchymal hepatic hemorrhage, suggesting early de-escalation to clopidogrel may be a safer strategy.
Answers are grounded in this paper and cite their sources.
Raises awareness for rare ticagrelor-related intrahepatic hemorrhage in ACS; leaves open whether de-escalation mitigates risk.
Ticagrelor is a potent P2Y12 inhibitor that is increasingly used in acute coronary syndrome. Although drug-related intrahepatic hemorrhages have been reported with anticoagulant drugs, no case of intrahepatic hemorrhage due to ticagrelor has been encountered in the literature. With this case, we tried to explain that potent antiaggregant drugs may cause this rare bleeding complication. Although ticagrelor is used for rapid antiaggregation effect in acute coronary syndrome, de-escalation to clopidogrel treatment in elderly patients during the hospitalization period is a more reasonable option.
No takes yet. Share an insight, caveat, or question.
Kaynak et al. (2021) conducted a case report in Acute Coronary Syndrome (n=1). Ticagrelor was evaluated on Intraparenchymal hepatic hemorrhage. A 78-year-old female with acute coronary syndrome developed a rare intraparenchymal hepatic hemorrhage following a loading dose of ticagrelor, resolving after de-escalation to clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: